EDGAR·FLOW

GT Biopharma, Inc. — Form 8-K

Filed September 21, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 92/100
What the filing says
GT Biopharma closed a securities purchase on September 18, 2026, issuing 8,611.1111 shares of Series M 10% Convertible Preferred Stock (with stated value of $8.61M) for $7.75M cash to Five Narrow Lane, L.P., Bristol Investment Fund, Ltd., and newly added investor Nicholas R. Nikolov. The amendment also grants purchasers Greenshoe rights to purchase up to $34.68M additional stated value of preferred stock for $31.21M. Series M share count increased from 41,778 to 43,287 authorized shares.
Why this rating

Raises ~90% of company's $8.6M market value in fresh capital with follow-on optionality; highly dilutive but critical for microcap survival and growth.

Tradability signal
NO TRADE

No trade: positive news with only -0.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -4.27% over 4 hrs, n=6). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$7.18 ▲ 0.00%
at our read · unknown
$7.18
+10 min · unknown
$7.00 ▼ 2.51%
+30 min · unknown
$7.00 ▼ 2.51%
+1 hr · unknown
$6.75 ▼ 5.99%
+4 hrs · unknown
$6.74 ▼ 6.13%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ GTBP · stock on Yahoo Finance ↗

See more from September 21, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.